EP3534964A4 - Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome - Google Patents

Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome Download PDF

Info

Publication number
EP3534964A4
EP3534964A4 EP17868118.5A EP17868118A EP3534964A4 EP 3534964 A4 EP3534964 A4 EP 3534964A4 EP 17868118 A EP17868118 A EP 17868118A EP 3534964 A4 EP3534964 A4 EP 3534964A4
Authority
EP
European Patent Office
Prior art keywords
enhancement
proteasome inhibitors
blockade therapy
blockade
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17868118.5A
Other languages
German (de)
English (en)
Other versions
EP3534964A1 (fr
Inventor
Emma LINDEROTH
Natasja Nielsen VILLER
Robert Adam Uger
Penka Slavcheva SLAVOVA-PETROVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Publication of EP3534964A1 publication Critical patent/EP3534964A1/fr
Publication of EP3534964A4 publication Critical patent/EP3534964A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP17868118.5A 2016-11-03 2017-11-01 Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome Pending EP3534964A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416936P 2016-11-03 2016-11-03
PCT/CA2017/051300 WO2018081897A1 (fr) 2016-11-03 2017-11-01 Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome

Publications (2)

Publication Number Publication Date
EP3534964A1 EP3534964A1 (fr) 2019-09-11
EP3534964A4 true EP3534964A4 (fr) 2020-07-15

Family

ID=62075506

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17868118.5A Pending EP3534964A4 (fr) 2016-11-03 2017-11-01 Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome

Country Status (4)

Country Link
US (2) US11446315B2 (fr)
EP (1) EP3534964A4 (fr)
CA (1) CA3042581A1 (fr)
WO (1) WO2018081897A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3534965A4 (fr) 2016-11-03 2020-06-24 Trillium Therapeutics Inc. Améliorations de la thérapie de blocage de cd47 par des inhibiteurs de hdac
WO2018081897A1 (fr) * 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome
WO2018236904A1 (fr) * 2017-06-19 2018-12-27 Surface Oncology, Inc. Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations
EP3661965A4 (fr) 2017-08-02 2022-07-13 Phanes Therapeutics, Inc. Anticorps anti-cd47 et leurs utilisations
CA3080640C (fr) 2017-11-06 2024-04-09 Trillium Therapeutics Inc. Blocage du cd47 associe a une radiotherapie
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CN109224079B (zh) * 2018-11-26 2020-08-04 中国药科大学 Dna甲基转移酶抑制剂与抗cd47抗体联合用于制备抗肿瘤药物的医药用途
EP3886915A4 (fr) * 2018-11-29 2022-10-19 PF Argentum IP Holdings LLC Biomarqueurs pour une thérapie de blocage de cd47
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
IL293199A (en) 2019-11-27 2022-07-01 Alx Oncology Inc Combined therapies for cancer treatment
CA3178157A1 (fr) 2020-06-01 2021-12-09 Jaume Pons Polytherapies comprenant un agent d'hypomethylation pour le traitement du cancer
WO2022010806A1 (fr) 2020-07-06 2022-01-13 ALX Oncology Inc. Procédés pour réduire l'interférence de médicaments qui se lient à des cibles thérapeutiques exprimées sur des cellules sanguines dans des dosages sérologiques
EP4256336A1 (fr) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimères pour réduire l'interférence de médicaments qui se lient à cd47 dans des dosages sérologiques
MX2023013259A (es) 2021-05-13 2023-11-27 Alx Oncology Inc Terapias de combinacion para el tratamiento del cancer.
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
WO2024040151A1 (fr) * 2022-08-18 2024-02-22 Pfizer Inc. Polythérapies de protéine de fusion sirp alpha et d'anticorps anti-cd38

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913894B2 (en) * 1999-11-30 2005-07-05 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies directed against signal regulator proteins
WO2015021376A1 (fr) * 2013-08-08 2015-02-12 Onyx Therapeutics, Inc. Niveaux d'expression d'immunoglobuline comme biomarqueur de la réponse inhibitrice du protéasome

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP2011500005A (ja) 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
CA3221018A1 (fr) 2008-01-15 2009-07-23 Ravindra Majeti Marqueurs des cellules souches de la leucemie myeloide aigue
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
EP2111869A1 (fr) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions et procédés pour renforcer le système immunitaire
JP2012512640A (ja) 2008-12-19 2012-06-07 ノバルティス アーゲー 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド
WO2010083253A2 (fr) 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Compositions associées au cd47 et procédés de traitement de maladies et de troubles immunologiques
HUE065432T2 (hu) 2009-05-15 2024-05-28 Univ Health Network Készítmények és eljárások a Sirp alfa-CD47 kölcsönhatást célzó hematológiai rákok kezelésére
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
PL3789038T3 (pl) 2010-05-14 2023-01-23 The Board Of Trustees Of The Leland Stanford Junior University Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
CA2824279A1 (fr) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Anticorps modifie presentant une demi-vie amelioree
EP2565186A1 (fr) * 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
RS60606B1 (sr) 2012-01-17 2020-08-31 Univ Leland Stanford Junior Reagensi sirp-alfa visokog affiniteta
CN111533804A (zh) 2012-02-06 2020-08-14 印希彼有限公司 Cd47抗体及其使用方法
AU2013302269A1 (en) * 2012-08-14 2015-03-12 Trillium Therapeutics Inc. Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
CN105102479B (zh) 2012-12-12 2019-06-28 瓦斯库劳克斯有限公司 治疗性cd47抗体
LT2931752T (lt) * 2012-12-17 2019-12-10 Trillium Therapeutics Inc Ligos cd47+ ląstelių gydymas su sirp alfa-fc junginiais
CA2900468C (fr) 2013-02-06 2024-04-30 Inhibrx Llc Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes
US20170224730A1 (en) * 2014-06-10 2017-08-10 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN106535914B (zh) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
WO2016022971A1 (fr) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Protéines de fusion sirp alpha-anticorps
US11021694B2 (en) 2014-08-15 2021-06-01 Merck Patent Gmbh SIRP-α immunoglobulin fusion proteins
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
CN114425077A (zh) * 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
JP2018535692A (ja) * 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法
AU2017250029C1 (en) 2016-04-15 2022-03-24 Pfizer Inc. Macrophage stimulation in CD47 blockade therapy
CA3040440C (fr) * 2016-07-15 2022-12-13 Korea Institute Of Science And Technology Nouvelle nanocage et utilisation associee
EP3534965A4 (fr) 2016-11-03 2020-06-24 Trillium Therapeutics Inc. Améliorations de la thérapie de blocage de cd47 par des inhibiteurs de hdac
WO2018081897A1 (fr) * 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome
CA3057718A1 (fr) 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Therapie par blocage de cd47
WO2018236904A1 (fr) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913894B2 (en) * 1999-11-30 2005-07-05 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies directed against signal regulator proteins
WO2015021376A1 (fr) * 2013-08-08 2015-02-12 Onyx Therapeutics, Inc. Niveaux d'expression d'immunoglobuline comme biomarqueur de la réponse inhibitrice du protéasome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLPORT JENNIFER R ET AL: "Endothelial-dependent mechanisms regulate leukocyte transmigration: a process involving the proteasome and disruption of the vascular endothelial-cadherin complex at endothelial cell-to-cell junctions", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 186, no. 4, 1 January 1997 (1997-01-01), pages 517 - 527, XP009520756, ISSN: 0022-1007, DOI: 10.1084/JEM.186.4.517 *
LINDEROTH E ET AL: "Abstract 2653: The anti-myeloma activity of TTI-621 (SIRP[alpha]Fc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor", vol. 77, no. 13, Supplement 1, 1 July 2017 (2017-07-01), pages 2653, XP009520755, ISSN: 1538-7445, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/77/13_Supplement/2653> DOI: 10.1158/1538-7445.AM2017-2653 *
See also references of WO2018081897A1 *

Also Published As

Publication number Publication date
CA3042581A1 (fr) 2018-05-11
US20230087443A1 (en) 2023-03-23
EP3534964A1 (fr) 2019-09-11
US11446315B2 (en) 2022-09-20
WO2018081897A1 (fr) 2018-05-11
US20190255082A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
EP3534964A4 (fr) Amélioration de la thérapie de blocage des cd47 par des inhibiteurs du protéasome
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
EP3600318A4 (fr) Procédés d&#39;utilisation d&#39;inhibiteurs d&#39;ehmt2
EP3579833A4 (fr) Procédés pour traiter la grippe
EP3233846A4 (fr) Inhibiteurs de bromodomaines
EP3289510A4 (fr) Détermination de la source d&#39;un logiciel externe
EP3204040A4 (fr) Traitement du cancer par agoniste(s) du tlr9 avec des inhibiteurs du point de contrôle
EP3220909A4 (fr) Procédés de modulation de niveaux de médicament dans le plasma au moyen d&#39;érythrohydroxybupropion
EP3137169A4 (fr) Inhibiteurs de la déméthylase-1 spécifiques de la lysine
EP3189038A4 (fr) Inhibiteurs de la déméthylase 1 spécifique de la lysine
EP3160956A4 (fr) Inhibiteurs de la déméthylase-1 spécifique de la lysine
EP3386590A4 (fr) Inhibiteurs bicycliques de pad4
EP3164380A4 (fr) Inhibiteurs de la déméthylase-1 spécifique de la lysine
EP3148543A4 (fr) Modulateurs de la transcription de petite molécule de bromodomaines
EP3240571A4 (fr) Formulation d&#39;anticorps thérapeutiques aglycosylés
EP3164509A4 (fr) Inhibiteurs de la déméthylase 1 spécifique de la lysine
EP3534965A4 (fr) Améliorations de la thérapie de blocage de cd47 par des inhibiteurs de hdac
EP3204009A4 (fr) Inhibiteurs de biosynthèse d&#39;héparane sulfate pour traiter des maladies
EP3197455A4 (fr) Inhibiteurs de la hif prolyl hydroxylase
EP3174832A4 (fr) Procédés pour traiter le système de plomberie de locaux
EP3152195A4 (fr) Inhibiteurs mth1 pour le traitement du cancer
EP3107619A4 (fr) Traitement par hydrogel et plasma
EP3119390A4 (fr) Méthodes de traitement du cancer
EP3139956A4 (fr) Méthodes d&#39;utilisation d&#39;anticorps anti-ang2
EP3297619A4 (fr) Utilisations thérapeutiques de la l-4-chlorocynurénine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200616

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/07 20060101ALI20200609BHEP

Ipc: A61K 31/69 20060101ALI20200609BHEP

Ipc: C07K 5/078 20060101ALI20200609BHEP

Ipc: C07K 19/00 20060101ALI20200609BHEP

Ipc: A61P 35/00 20060101ALI20200609BHEP

Ipc: C07K 7/06 20060101ALI20200609BHEP

Ipc: A61K 38/17 20060101ALI20200609BHEP

Ipc: C07K 14/705 20060101ALI20200609BHEP

Ipc: A61K 38/05 20060101ALI20200609BHEP

Ipc: A61K 47/68 20170101AFI20200609BHEP

Ipc: C07F 5/04 20060101ALI20200609BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PF ARGENTUM IP HOLDINGS LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220629

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PFIZER INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230417